



**US Headquarters**  
21250 Hawthorne Blvd.  
Suite 800  
Torrance, CA 90503, USA  
Tel: 310.214.0065  
Fax: 310.214.0075  
www.emmausmedical.com

**European Offices**  
Emmaus Medical Europe Limited  
1 Anglesea Lane, Corrig Avenue  
Dun Laoghaire, Co. Dublin  
A96 VK65  
Ireland

---

18 September 2019

CHMP Chairman  
European Medicines Agency  
Domenico Scartlattiann 6  
1083 HS Amsterdam  
The Netherlands

**Subject: Withdrawal of Xyndari™, glutamine, 5 grams, oral powder - EMEA/H/C/004734**

Dear CHMP Chairman,

I would like to inform you that, at this point of time, Emmaus Medical Europe Limited (Emmaus) has taken the decision to withdraw the application for Marketing Authorisation of Xyndari™, glutamine, 5 grams, oral powder, which was intended to be used for the treatment of sickle cell disease.

This withdrawal is based on the change in the Company's marketing strategy.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

Emmaus will continue to support the ongoing compassionate use program(s) pending further discussion with relevant local competent authorities which have granted approval for compassionate use.

I agree for this letter to be published on the EMA website.

Yours sincerely,